DPP4 and metabolic dysfunction-associated steatotic liver disease: Although there is growing in vivo and in vitro evidence suggesting the potential benefits of DPP-4 inhibitors for NAFLD treatment, there are only a few clinical trials demonstrating significant efficacy in affected patients.